Lenalidomide oral sustained release formulation (Starton Therapeutics)

来那度胺口服缓释剂型 (Starton Therapeutics)

Report date: 2025/06/26 11:11:59

Base Information

Drug NameLenalidomide oral sustained release formulation (Starton Therapeutics)
Drug Alias NameOral Controlled Release Dosage Form of STAR-LLD (lenalidomide)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionCereblon modulatorsDNA-binding protein Ikaros degradersZinc finger protein Aiolos degraders +[4] 
TargetsCereblonDNA-binding protein IkarosZinc finger protein Aiolos +[4] 
Therapy Area/IndicationsMultiple MyelomaLeukemia, Lymphocytic, Chronic, B-Cell
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesStarton Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesStarton Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsMultiple MyelomaLeukemia, Lymphocytic, Chronic, B-Cell
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A